Leslie Meltzer

Leslie joined Orchard Therapeutics in June 2018 bringing extensive experience leading medical affairs for several premier biopharmaceutical companies. Throughout her career, Leslie led the integration of medical functions across brands including publication planning, field team training, advisory boards, patient registry and identification efforts, investigator-initiated trial prioritization, and post-marketing planning. A neuroscientist by training, Leslie has dedicated much of her career to advancing new therapies for difficult-to-treat brain diseases.

She joined Orchard Therapeutics from Keryx Biopharmaceuticals (prior to its merger with Akebia Therapeutics) where she served as vice president of medical affairs. She previously served in various positions of increasing seniority in medical affairs at Biogen, where she led key elements of U.S. launch and post-launch activities in multiple sclerosis. In recognition of her success and contributions, Leslie was promoted to leadership roles in Biogen’s multiple sclerosis and then its hemophilia franchises, comprising the company’s approved and investigational therapies. Leslie began her career at Actelion (now part of Janssen) where she supported a variety of therapeutic areas, including respiratory, cardiovascular, rheumatology, neurology, and rare disease.

Leslie earned her Ph.D. in neuroscience from Stanford University School of Medicine.